Business
Biden announces cancellation of an additional $1.2 billion in student loan debt for about 153,000 borrowers.
President Joe Biden announcing the cancellation of an additional $1.2 billion in student loan debt (Irfan Khan/Getty Images)
Weird Money

How PE firms could be the unlikely beneficiaries of Biden's student-loan forgiveness plan

Private equity is buying up private student loan debt by the billions. The government forgiving federal student debt could make their purchases less risky.

Jack Raines

In the latest rendition of “private equity firms are eating the world,” KKR and Carlyle have acquired $10 billion in private student loans from Discover Financial, per The Wall Street Journal:

Private-equity firms are helping traditional lenders shed credit risks by acquiring student loans even as debt forgiveness remains a hot topic in Washington. 

Carlyle Group and KKR underlined the trend in July, when they bought a $10.1 billion portfolio of private student loans at auction from Discover Financial Services, a digital banking and payment services company, with the purchase price expected to reach about $10.8 billion once the deal closes later this year. Half of the loans carry fixed rates and the rest have floating rates, according to the asset managers... 

My first thought when reading this was: “Why?” Yes, these firms have billions of dollars that need to be deployed somewhere, but student loans seemed odd, especially considering the Biden administration’s insistence on forgiving billions of dollars of student loans. However, this forgiveness is actually a tailwind for the loans that these funds purchased, according to Carlyle’s head of credit strategic solutions, Akhil Bansil:

“Forgiveness of the federal student loans can be a credit positive for us as the private student loan owners,” Bansal said. “If the government were to forgive the federal loans, that makes that student more creditworthy to service our loan.” 

Most student borrowers take out both federal and private loans, with interest rates as high as 9% on the former compared with as high as 17% for the latter, according to consumer financial-services company Bankrate.

How does that make sense? Because Biden’s student loan forgiveness plan applies to federal loans, which were issued by the government, not private loans such as those purchased by Carlyle and KKR. 

While the Supreme Court blocked the Biden administration’s attempt to forgive $430 billion in student loans, the White House has still approved nearly $169 billion in loan forgiveness for ~4.8 million people, and according to CNBC, the president may start forgiving this student debt as early as October.

As the Journal piece mentioned, “most student borrowers take out both federal and private loans,” so, if Biden were to forgive $169 billion in federal debt, those borrowers would be able to more easily repay their private loans, many of which are now held by KKR and Carlyle. Basically, the White House's student loan forgiveness plan, while helping borrowers, also had a wild unintended consequence: derisking the loan portfolios of two of the world's largest PE funds.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.